聚焦
2017年5月16日至18日，藥石科技PharmaBlock美國(guó)商務(wù)拓展團(tuán)隊(duì)參加了在費(fèi)城舉辦的，世界制藥原料北美展暨美國(guó)國(guó)際精細(xì)化工展覽會(huì)(CPhI North America & InformEx)。今年是CPhI在美國(guó)的首秀，主辦地費(fèi)城是全球醫(yī)藥行業(yè)最發(fā)達(dá)的城市之一，周邊匯聚了超過(guò)3000家世界領(lǐng)先的制藥公司、生物技術(shù)企業(yè)和研發(fā)機(jī)構(gòu)，為這次展會(huì)帶來(lái)了更多新的機(jī)遇。
在CPhI NA舉辦期間，由C&EN (美國(guó)化學(xué)會(huì)旗下《化學(xué)與工程新聞》雜質(zhì)) 出版的會(huì)刊Show Daily專門對(duì)藥石科技進(jìn)行了報(bào)道，刊登了有關(guān)藥石科技與全球頂尖研發(fā)型制藥企業(yè)Agios Pharmaceutical Inc. 簽訂商業(yè)化供應(yīng)合作協(xié)議的消息。
藥石科技憑借在合成化學(xué)、工藝開(kāi)發(fā)和生產(chǎn)方面的卓越能力，正在為越來(lái)越多的客戶在新藥研究、開(kāi)發(fā)和商業(yè)化的過(guò)程中提供更全面的產(chǎn)品和服務(wù)，建立長(zhǎng)期穩(wěn)定的合作關(guān)系。
（打開(kāi)Show Daily閱讀全文）
圖：Show Daily藥石科技報(bào)道
圖：藥石科技美國(guó)商務(wù)拓展團(tuán)隊(duì)參展
READ THE NEWS
報(bào)道全文
PharmaBlock Inks New Commercial Supply Agreement with Agios
PharmaBlock Sciences (Nanjing), Inc., a leading innovative chemistry products and services provider throughout the pharmaceutical R&D process, has entered a new Commercial Supply Agreement for Drug Substance Starting Materials with Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, as part of the commercial launch readiness.
Under this agreement, PharmaBlock will continuously provide Agios with drug substance starting materials and intermediates for commercial production.
PharmaBlock and Agios have been involved in a long-term collaboration, from synthesis of lab-scale building blocks to bulk manufacturing of RSMs, as Agios’ drug R&D project moves on to later development stages. “We are pleased to have PharmaBlock as our strategic partner. With their capabilities in medicinal synthesis, process R&D, and manufacturing, we have collaborated from research to development to commercial.” said Ms. Wendy Xia, Director of Commercial Supplies at Agios, “It is an exciting story that we both experience the ‘scale-up’ together, and enter this commercial partnership eventually.”
"The Commercial Supply Agreement further strengthens our already productive relationship with Agios, one of our most valued customers for many years. It is our honor to be a part of Agios’ life-saving drug R&D projects and witness every milestone they have achieved along the way. We will continue to deliver our firm commitment to quality and custom satisfaction.” said Dr. Haijun Dong, Chief Executive Officer of PharmaBlock.